Nektar Therapeutics reports results for the quarter ended June 30 - Earnings Summary

Nektar Therapeutics

13/08/2026 22:39

Nektar Therapeutics NKTR.OQ reported a quarterly adjusted loss of $1.23​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-2.95.  The mean expectation of eleven analysts for the quarter was for a loss of $1.98 per share. Wall Street expected results to range from $-2.50 to $-1.68 per share.
Revenue fell 9.3% to $10.13 million from a year ago; analysts expected $10.42 million. 
Nektar Therapeutics's reported EPS for the quarter was a loss of $1.23​.
The company reported a quarterly loss of $40.62 million.
Nektar Therapeutics shares had risen by 8.9% this quarter and gained 79.8% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 2.7% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Nektar Therapeutics is $151.00, about 49.6% above its last closing price of $76.03
This summary was machine generated from LSEG data August 13 at 09:38 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-1.98
-1.23
Beat
Mar. 31 2026 
-1.59
-1.82
Missed
Dec. 31 2025 
-2.47
-1.78
Beat
Sep. 30 2025 
-2.68
-1.87
Beat